Invitro International
InVitro International, Inc. develops test kits for non-animal testing applications in the United States and internationally. Its products include Irritection Assay System, an invitro test, which utilizes the change of relevant macromolecules to predict the ocular and dermal irritancy of chemicals, mixtures, and product formulations; and Corrositex, a non-animal test that determines skin corrosivi… Read more
Invitro International (IVRO) - Net Assets
Latest net assets as of March 2024: $1.53 Million USD
Based on the latest financial reports, Invitro International (IVRO) has net assets worth $1.53 Million USD as of March 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.58 Million) and total liabilities ($55.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.53 Million |
| % of Total Assets | 96.52% |
| Annual Growth Rate | N/A |
| 5-Year Change | 18.7% |
| 10-Year Change | -48.04% |
| Growth Volatility | 365.57 |
Invitro International - Net Assets Trend (1989–2023)
This chart illustrates how Invitro International's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Invitro International (1989–2023)
The table below shows the annual net assets of Invitro International from 1989 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-09-30 | $1.46 Million | +0.92% |
| 2022-09-30 | $1.44 Million | +0.81% |
| 2021-09-30 | $1.43 Million | +7.79% |
| 2020-09-30 | $1.33 Million | +8.25% |
| 2019-09-30 | $1.23 Million | +12.81% |
| 2017-09-30 | $1.09 Million | +113.87% |
| 2008-09-30 | $508.06K | +15.30% |
| 2007-09-30 | $440.63K | -77.97% |
| 1996-09-30 | $2.00 Million | -28.57% |
| 1995-09-30 | $2.80 Million | -50.00% |
| 1994-09-30 | $5.60 Million | +21.74% |
| 1993-09-30 | $4.60 Million | +253.85% |
| 1992-09-30 | $1.30 Million | -78.33% |
| 1991-09-30 | $6.00 Million | +1400.00% |
| 1990-09-30 | $400.00K | +300.00% |
| 1989-09-30 | $-200.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Invitro International's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 241601000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (September 2023)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $716.01K | 49.21% |
| Common Stock | $654.08K | 44.95% |
| Other Comprehensive Income | $64.00K | 4.40% |
| Other Components | $20.93K | 1.44% |
| Total Equity | $1.46 Million | 100.00% |
Invitro International Competitors by Market Cap
The table below lists competitors of Invitro International ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AGROWILL GROUP
MU:W9Z
|
$817.17 |
|
Quality Hospitality Leasehold Property Fund
BK:QHOP
|
$817.98 |
|
Malvern International
LSE:MLVN
|
$820.81 |
|
Grupa Modne Zakupy S.A.
WAR:GMZ
|
$821.10 |
|
Ghandhara Tyre and Rubber Company Ltd
KAR:GTYR
|
$816.87 |
|
Marquie Group Inc
PINK:TMGI
|
$816.52 |
|
CPPGroup Plc
LSE:CPP
|
$815.98 |
|
Petrolera Pampa S.A
BA:PETR
|
$815.46 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Invitro International's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 1,441,809 to 1,455,017, a change of 13,208 (0.9%).
- Net income of 1,553 contributed positively to equity growth.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.55K | +0.11% |
| Other Changes | $11.65K | +0.8% |
| Total Change | $- | 0.92% |
Book Value vs Market Value Analysis
This analysis compares Invitro International's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.47x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1989-09-30 | $-0.11 | $0.09 | x |
| 1990-09-30 | $0.12 | $0.09 | x |
| 1991-09-30 | $1.51 | $0.09 | x |
| 1992-09-30 | $0.25 | $0.09 | x |
| 1993-09-30 | $0.74 | $0.09 | x |
| 1994-09-30 | $0.48 | $0.09 | x |
| 1995-09-30 | $0.23 | $0.09 | x |
| 1996-09-30 | $0.17 | $0.09 | x |
| 2019-09-30 | $0.06 | $0.09 | x |
| 2020-09-30 | $0.06 | $0.09 | x |
| 2021-09-30 | $0.06 | $0.09 | x |
| 2022-09-30 | $0.06 | $0.09 | x |
| 2023-09-30 | $0.06 | $0.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Invitro International utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.20%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 1.05x
- Recent ROE (0.11%) is above the historical average (-45.27%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1989 | 0.00% | -40.00% | 0.56x | 0.00x | $-180.00K |
| 1990 | 25.00% | 7.69% | 0.57x | 5.75x | $60.00K |
| 1991 | -58.33% | -700.00% | 0.08x | 1.05x | $-4.10 Million |
| 1992 | -392.31% | -364.29% | 0.58x | 1.85x | $-5.23 Million |
| 1993 | -80.43% | -194.74% | 0.35x | 1.17x | $-4.16 Million |
| 1994 | -78.57% | -258.82% | 0.26x | 1.16x | $-4.96 Million |
| 1995 | -100.00% | -254.55% | 0.34x | 1.14x | $-3.08 Million |
| 1996 | -90.48% | -172.73% | 0.46x | 1.14x | $-2.11 Million |
| 2007 | 15.72% | 9.34% | 1.47x | 1.14x | $25.21K |
| 2008 | 12.82% | 9.35% | 1.20x | 1.15x | $14.34K |
| 2017 | 4.40% | 5.59% | 0.74x | 1.07x | $-60.82K |
| 2019 | 5.77% | 6.71% | 0.76x | 1.13x | $-51.90K |
| 2020 | 3.76% | 4.52% | 0.72x | 1.16x | $-82.79K |
| 2021 | 6.71% | 9.57% | 0.61x | 1.14x | $-47.04K |
| 2022 | 1.48% | 2.49% | 0.57x | 1.05x | $-122.90K |
| 2023 | 0.11% | 0.20% | 0.52x | 1.05x | $-143.95K |
Industry Comparison
This section compares Invitro International's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Invitro International (IVRO) | $1.53 Million | 0.00% | 0.04x | $816.93 |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |